🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Intuitive Surgical, Inc. ISRG NDXSPXR3KAIPHARMA

Healthcare · Medical Instruments & Supplies · United States
https://www.intuitive.com
Company Profile ↓
$366.70
-23.98% 1Y
Mkt Cap$131.38B
P/E42.10
P/B7.38
52W High$592.85
52W Low$332.02
Book Value$51.34
EPS (TTM)$8.71

Company Overview

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 17.4%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 16.0%.

Consistent Profit Growth

Net profit has compounded at 18.0% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 17.0% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 28.4%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $10.06B (+20.5% YoY); net profit $2.86B.
  • Trailing 12 Months Year-on-year growth — revenue +18.5%, earnings +26.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 17.0%, profit CAGR 18.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:16.95%
1 Year:18.50%

Compounded Profit Growth

5 Years:18.03%
1 Year:26.50%

Stock Price Performance

1 Year:-23.98%
6 Months:-25.19%
3 Months:-13.12%
1 Month:-1.88%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

AI Exposure AI Medical Technology / AI-Enabled Robotics

Intuitive Surgical makes the da Vinci surgical-robotics systems and is embedding AI/data analytics to improve minimally invasive surgery.

Core Focus

Robotic-assisted surgery (da Vinci) and endoluminal systems (Ion), with growing AI/data capabilities.

Key Initiatives
  • AI-enabled surgical robotics Intuitive is adding AI and data analytics to da Vinci to enhance surgical insight and outcomes.
  • Ion endoluminal robotics Its Ion system extends robotics into minimally invasive lung biopsy.
  • Data & learning platform Surgical data feeds analytics that improve technique and training.
Why Investors Should Care
  • Dominant surgical-robotics franchise with a razor-and-blade model; net ~28%.
  • Adding AI/data to deepen its moat and outcomes.
  • Premium valuation prices in durable growth.
  • Hospital-capex cycles and competition are watch items.
AI InvestmentInvestment embeds AI/data analytics into the surgical-robotics platform.
AI RevenueAI is a feature enhancing systems/instruments; it is not a separate disclosed line.
ROI (Now)AI/data deepen the value of the installed base today.
ROI (Expected)AI-driven surgical insight and automation could strengthen the long-term moat.

Curated from public filings and analyst commentary; figures are illustrative.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Excellent profit margin of 28.4%.
  • Compounding revenue at 17.0% over 5 years.
  • Profit CAGR of 18.0% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 38.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
42.10
Industry PE
25.17
Forward P/E
30.38
PEG Ratio
1.83
Book Value
$51.34
Price to Book
7.38
P/S
12.30
EV/EBITDA
30.79
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
16.95%
Profit 5Y
18.03%
Revenue (YoY)
18.50%
Earnings (YoY)
26.50%

Profitability & Returns

ROCE
15.96%
ROE
17.42%
ROA
10.51%
Profit Margin
28.45%
Op Margin
33.60%
Gross Margin
66.68%
EPS (Latest Qtr)
$2.29
EPS (TTM)
$8.71

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
3.64
Current Ratio
4.96
Debt
$0
Total Assets
$20.88B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
0.51%
Chg in Prom Hold
-0.00%
FII / Inst Holding
89.60%
Chg in FII Hold
0.03%

Financial Snapshot

Enterprise Value
$131.38B
Total Revenue (TTM)
$11.03B
EBITDA
$4.18B
Free Cash Flow
$2.62B
Operating Cash Flow
$3.71B
Shares Outstanding
358.28M
Gross Margin
66.68%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ISRG Intuitive Surgical, Inc. NDXSPXR3KAIPHARMA 366.70 42.10 $131.38B 0.00% 15.96% 17.42% 16.95% 18.03%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue ------679.60M758.80M807.80M892.00M847.50M909.30M920.90M1.05B973.70M1.10B1.13B1.28B1.10B852.10M1.08B1.33B1.29B1.46B1.40B1.55B1.49B1.52B1.56B1.70B1.76B1.74B1.89B2.01B2.04B2.25B2.44B2.51B2.77B2.89B
Gross Profit 395.80M458.80M405.00M470.90M487.00M527.20M469.80M530.10M568.10M634.00M593.80M632.30M642.30M735.70M669.60M759.00M785.60M896.00M738.20M502.90M724.30M895.80M902.60M1.02B971.40M1.06B1.01B1.02B1.05B1.11B1.17B1.17B1.25B1.37B1.37B1.46B1.62B1.66B1.83B1.96B
Operating Income 189.90M-179.00M245.40M256.40M-193.40M259.90M280.60M-276.70M277.40M313.30M-252.20M359.00M365.70M-283.00M80.60M270.40M-416.80M511.20M442.60M-408.10M397.60M398.90M387.60M463.20M465.80M469.40M567.30M577.30M578.10M743.40M759.70M855.30M971.90M
Net Income 167.30M190.00M136.40M184.50M211.00M204.00M180.80M223.00M298.60M-31.50M287.60M255.30M292.50M292.50M306.50M318.30M396.80M357.70M313.50M68.00M313.90M365.20M426.30M517.20M380.50M380.60M365.60M307.80M324.00M355.30M420.80M415.70M544.90M526.90M565.10M698.40M658.40M704.40M821.50M818.10M
Diluted EPS 4.404.991.181.571.771.711.571.942.56-0.282.442.152.452.452.562.673.332.992.620.572.603.021.171.421.041.031.000.850.901.001.181.161.511.461.561.921.811.952.282.29
R&D Expense 51.00M-53.20M54.70M62.60M-73.50M84.60M83.40M-95.50M95.10M107.60M-144.00M120.80M135.90M-147.10M143.20M155.00M-159.80M162.30M165.50M-210.50M207.30M217.10M244.90M244.40M249.40M284.50M280.10M286.00M316.20M313.30M329.40M361.90M370.60M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 600.83M874.90M1.05B1.41B1.76B2.18B2.27B2.13B2.38B2.71B3.14B3.72B4.48B4.36B5.71B6.22B7.12B8.35B10.06B
Gross Profit 414.29M620.80M751.10M1.03B1.27B1.57B1.59B1.41B1.58B1.89B2.20B2.60B3.11B2.86B3.96B4.20B4.73B5.63B6.64B
Operating Income 206.74M310.80M377.40M555.20M694.80M878.10M852.50M544.80M740.00M949.70M1.06B1.20B1.37B1.05B1.82B1.58B1.77B2.35B2.95B
Net Income 144.54M204.30M232.60M381.80M495.10M656.60M671.00M418.80M588.80M738.30M670.90M1.13B1.38B1.06B1.70B1.32B1.80B2.32B2.86B
Diluted EPS 3.705.125.939.4712.3215.9816.7311.115.186.265.779.493.852.944.663.655.036.427.87
R&D Expense 48.86M79.40M95.10M116.00M140.20M170.00M167.70M178.00M197.40M239.60M328.60M418.10M557.30M595.10M671.00M879.00M998.80M1.15B1.31B

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --1.47B1.81B2.39B3.06B4.06B3.95B3.96B4.91B6.49B5.78B7.85B9.73B11.17B13.55B12.97B15.44B18.74B20.46B
Total Equity 589.71M888.70M1.27B1.54B2.04B2.65B3.58B3.50B3.38B4.32B5.78B4.78B6.68B8.26B9.73B11.90B11.04B13.31B16.43B17.82B
Cash & Equivalents 34.39M122.80M194.60M221.40M279.80M465.80M553.70M782.10M600.30M714.60M1.04B648.20M857.90M1.17B1.62B1.29B1.58B2.75B2.03B3.37B
Total Liabilities --207.86M272.40M353.00M417.50M479.10M448.90M580.00M587.80M709.10M996.40M1.16B1.45B1.41B1.60B1.86B2.04B2.21B2.52B
Current Liabilities --164.52M202.80M273.80M320.60M401.60M380.90M501.20M491.90M596.50M662.80M820.60M1.03B965.20M1.15B1.42B1.66B1.75B2.01B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 205.69M278.20M392.20M545.80M677.60M814.20M880.00M665.10M806.20M1.09B1.14B1.17B1.60B1.48B2.09B1.49B1.81B2.42B3.03B
Investing Cash Flow -236.40M-304.50M-299.50M-494.30M-479.00M-845.70M259.00M-153.90M-849.50M-1.28B378.70M-1.05B-1.15B-940.60M-2.46B1.37B-360.10M-3.27B665.80M
Financing Cash Flow 118.85M98.00M-66.20M7.70M-12.40M119.20M-910.60M-692.40M159.10M514.40M-1.91B126.30M-168.40M-85.70M43.00M-2.57B-287.60M150.90M-2.36B
Share Buybacks 00150.00M198.60M331.80M238.30M1.11B1.00B183.70M42.50M2.27B0269.50M134.30M02.61B416.30M02.30B

Ratios (Annual)

Figures in %.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 69.0%71.0%71.4%72.9%72.5%72.1%70.4%66.3%66.2%69.9%70.2%69.9%69.4%65.6%69.3%67.4%66.4%67.5%66.0%
Operating Margin % 34.4%35.5%35.9%39.3%39.5%40.3%37.6%25.6%31.0%35.1%33.9%32.2%30.7%24.1%31.9%25.3%24.8%28.1%29.3%
Net Margin % 24.1%23.4%22.1%27.0%28.2%30.1%29.6%19.6%24.7%27.3%21.4%30.3%30.8%24.3%29.9%21.3%25.2%27.8%28.4%
ROE % 16.3%16.1%15.1%18.7%18.7%18.3%19.2%12.4%13.6%12.8%14.0%16.9%16.7%10.9%14.3%12.0%13.5%14.1%16.0%
ROCE % -23.7%23.5%26.2%25.3%24.0%23.9%15.8%16.8%16.1%20.8%17.1%15.8%10.3%14.7%13.7%12.8%13.8%16.0%

Shareholding Pattern

Insiders
0.51%
Institutions
89.60%
Public Float
90.06%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.50% 30.02M $11.19B
2 Vanguard Capital Management LLC 6.55% 23.13M $8.62B
3 State Street Corporation 4.55% 16.06M $5.99B
4 Invesco Ltd. 3.35% 11.84M $4.41B
5 Price (T.Rowe) Associates Inc 3.19% 11.26M $4.19B
6 Geode Capital Management, LLC 2.42% 8.53M $3.18B
7 Capital World Investors 2.19% 7.74M $2.88B
8 Vanguard Portfolio Management LLC 2.05% 7.24M $2.70B
9 Morgan Stanley 1.86% 6.56M $2.44B
10 NORGES BANK 1.40% 4.95M $1.85B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ISRG

Google News Mon, 07 Sep 2026

Intuitive Surgical, Inc. (ISRG) Stock Analysis: A 30% Upside Potential Beckons Investors - DirectorsTalk Interviews

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxONDBMRkdPN2EzVkcybGRuYmQxNmhLSEZqT1pmamI3UHdmSW1sd0duYjNkNUxQX052Tk5aLTFaUE5FVjJORkM5d1JNM2pPd3ZLYlNvWi1ZM2xmeW9wdnN6S21OLTg1X0I5Qm1VbVJNQTFNaGNyZDdvNnVyU2xxeGQyWHR4WnJwcTRqV2pQdk…

Google News Wed, 02 Sep 2026

ISRG Stock: The Best House On The Block Costs The Most - Trefis

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOOTdpbHJwd0RHY1ZteFRIcFQ4YzM4LTMyM0trSnRpQTVoYTQ3akdaalk3Qm1ySXE3UU1XRmRmY2ExSG1ScUN3V0RZeF9SQWlKOTktNVp1VmVjU19wOGJVTFJNMnpDdU45RmttemJXZV9tMC1mVXFDWjVvSW5xRnZUMFkxTHROaVpjbjhBdn…

Google News Mon, 07 Sep 2026

ISRG's Ion Platform Is Quietly Becoming a Second Growth Engine - TradingView

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPQ3JHd2x3X3NWa0JtOXhrVV9va05CdDhpM1VBOFAyNjMxa3l4R1V5MF9FeVotT3cwTGF6V2ZhNnpSTTV0WVBpaFBJblJ3ejlXMWNJT01kZFpVV3ZlRXZkYzZ6R0ZDVGZTblM5VGwxQzh2NGNodzZrMWdENHpqblRzbE5wMWdQNDlrNXZZRE…

Google News Sun, 06 Sep 2026

Intuitive Surgical (ISRG) Down 30% This Year; Can Tonight’s Q2 Earnings Reverse the Bearish Channel? - tradingkey.com

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQZTVzVTNjbnlwcWhybkVTU2tnbEZlU1haWVJnQVBSYmdPSFQtV0FJU3d6V3pwV1pKa2k3TzVCUDcyNFpvTUlqTFFmVXZlNUNScFRjZGlXUW5nMU55cnoySUV6WWtyYlNkSjRLYkRVTkFOUFk5QUc0b1FldUd6MnIxY2pTTnpEMnN6dzE1TG…

Google News ue, 18 Aug 2026

Intuitive Surgical Stock Is Having Its Worst Year Since 2008. What's Behind the Sell-Off? - The Motley Fool

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOUUdBU2tBb2RtZjF1bDI0TkQtMlFLY1Z6bjQ5U0lJblJNbHRac0gyMHlacEFCcFlWeTVPYWF6YnhWdmZYYmU4RUczN0JWakRVQ3J2Qi1SbFlGc0p4V1NYNDQtOFVpNmZiYUd3SUZXTWNFaV8za0tTaURsWTJJai13UXQ1eUtNa1hrUmhQY2…

Google News Mon, 07 Sep 2026

Is Slower da Vinci Placements Refocusing Intuitive Surgical’s (ISRG) Investment Case On Utilization Economics? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQeWMtLW9hcEVwNUNqWDJoM0lJdnZrSFk2WEF0NUtFY1k5eFJlSGtDRnZLeTdSZ2FPVFNRSDQwTDFKNU9yZHpwYjhBVTVqZmtuU2xPY0tkdXRhN3RhQ2pqOXZBTThVRUk4SjQzSkpDSkI1eFVqVGg1U2pSRm1vQmlCNEdUUTZUX3hiLXVZQ2…

ISRG — Frequently Asked Questions

What is the current share price of Intuitive Surgical, Inc. (ISRG)?

As of 2026-09-07 16:24 PDT, Intuitive Surgical, Inc. (ISRG) trades at $366.70 on NasdaqGS. Its 52-week range is $332.02 to $592.85.

What is the market capitalisation of ISRG?

Intuitive Surgical, Inc. (ISRG) has a market capitalisation of $131.38B on NasdaqGS.

What is the P/E ratio of ISRG?

ISRG trades at a trailing price-to-earnings (P/E) ratio of 42.10. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 7.38.

What is the return on equity (ROE) of ISRG?

ISRG has a return on equity (ROE) of 17.42%. Its return on capital employed (ROCE) is 15.96%.

Is ISRG a good stock to buy?

This page provides a data-driven analysis of Intuitive Surgical, Inc. (ISRG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space